Suo L, Chang X, Xu N, Ji H. The anti-proliferative activity of GnRH through downregulation of the Akt/ERK pathways in pancreatic cancer. Front Endocrinol. 2019;10:370.
Gründker C, Ernst J, Reutter M, Ghadimi BM, Emons G. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers. Oncol Rep. 2011;26:629–35.
Google Scholar
Maggi R, Cariboni AM, Marelli MM, Moretti RM, Andrè V, Marzagalli M, et al. GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. Hum Reprod Update. 2016;22:358–81.
Google Scholar
Gründker C, Emons G. The role of gonadotropin-releasing hormone in cancer cell proliferation and metastasis. Front Endocrinol. 2017;8:187.
Föst C, Duwe F, Hellriegel M, Schweyer S, Emons G, Gründker C. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. Oncol Rep. 2011;25:1481–7.
Google Scholar
Seitz S, Buchholz S, Schally AV, Weber F, Klinkhammer-Schalke M, Inwald EC, et al. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125. BMC Cancer. 2014;14:847.
Kwok CW, Treeck O, Buchholz S, Seitz S, Ortmann O, Engel JB. Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). Target Oncol. 2015;10:365–73.
Google Scholar
Li X, Taratula OO, Taratula OO, Schumann C, Minko T. LHRH-targeted drug delivery systems for cancer therapy. Mini Rev Med Chem. 2016;17:258–67.
Limonta P, Marelli MM, Mai S, Motta M, Martini L, Moretti RM. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev. 2012;33:784–811.
Google Scholar
Engel JB, Tinneberg H-R, Rick FG, Berkes E, Schally AV. Targeting of peptide cytotoxins to LHRH receptors for treatment of cancer. Curr Drug Targets. 2016;17:488–94.
Google Scholar
Fontana F, Marzagalli M, Marelli MM, Raimondi M, Moretti RM, Limonta P. Gonadotropin-releasing hormone receptors in prostate cancer: molecular aspects and biological functions. Int J Mol Sci. MDPI AG. 2020;21:1–23.
Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser HP, et al. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol. 2000;17:1063–9.
Google Scholar
Miller DS, Scambia G, Bondarenko I, Westermann AM, Oaknin A, Oza AM, et al. ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155). J Clin Oncol. 2018;36:5503–5503.
Curtis KK, Sarantopoulos J, Northfelt DW, Weiss GJ, Barnhart KM, Whisnant JK, et al. Novel LHRH-receptor-targeted cytolytic peptide, EP-100: First-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. Cancer Chemother Pharmacol. 2014;73:931–41.
Google Scholar
Davenport AP, Scully CCG, de Graaf C, Brown AJH, Maguire JJ. Advances in therapeutic peptides targeting G protein-coupled receptors. Nat Rev Drug Discov. 2020;19:389–413.
Google Scholar
Ball BA, Sabeur K, Nett T, Liu IKM. Effects of a GnRH cytotoxin on reproductive function in peripubertal male dogs. Theriogenology. 2006;66:766–74.
Google Scholar
Sabeur K, Ball BA, Nett TM, Ball HH, Liu IKM. Effect of GnRH conjugated to pokeweed antiviral protein on reproductive function in adult male dogs. Reproduction. 2003;125:801–6.
Google Scholar
Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovacs M, et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA. 1996;93:7269–73.
Google Scholar
Nagy A, Plonowski A, Schally AV. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: Implications for the design of preclinical studies. Proc Natl Acad Sci USA. 2000;97:829–34.
Google Scholar
Struthers RS. Gonadotropin-releasing hormone targeting for gonadotroph ablation: an approach to non-surgical sterilization. Reprod Domest Anim. 2012;47:233–8.
Google Scholar
Kovacs M, Schally AV, Nagy A, Koppan M, Groot K. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA. 1997;94:1420–5.
Google Scholar
Kovacs M, Schally AV, Csernus B, Busto R, Rekasi Z, Nagy A. Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH. J Neuroendocrinol. 2002;14:5–13.
Google Scholar
Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575:299–309.
Google Scholar
Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18:452–64.
Google Scholar
Dawson MA. The cancer epigenome: concepts, challenges, and therapeutic opportunities. Science. 2017;355:1147–52.
Google Scholar
Gilan O, Rioja I, Knezevic K, Bell MJ, Yeung MM, Harker NR, et al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science. 2020;368:387–94.
Google Scholar
Ayyanathan K, Lechner MS, Bell P, Maul GG, Schultz DC, Yamada Y, et al. Regulated recruitment of HP1 to a euchromatic gene induces mitotically heritable, epigenetic gene silencing: a mammalian cell culture model of gene variegation. Genes Dev. 2003;17:1855–69.
Google Scholar
Alerasool N, Segal D, Lee H, Taipale M. An efficient KRAB domain for CRISPRi applications in human cells. Nat Methods. 2020;17:1093–6. https://pubmed.ncbi.nlm.nih.gov/33020655/
Google Scholar
O’Geen H, Bates SL, Carter SS, Nisson KA, Halmai J, Fink KD, et al. Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner. Epigenet Chromatin. 2019;12:26.
Miranda Furtado CL, Dos Santos Luciano MC, Silva Santos R Da, Furtado GP, Moraes MO, et al. Epidrugs: targeting epigenetic marks in cancer treatment. Epigenetics. 2019;14:1164–76.
Hogg SJ, Beavis PA, Dawson MA, Johnstone RW. Targeting the epigenetic regulation of antitumour immunity. Nat Rev Drug Discov. 2020;19:776–800.
Google Scholar
Wimalasena VK, Wang T, Sigua LH, Durbin AD, Qi J. Using chemical epigenetics to target cancer. Mol Cell Cell Press. 2020;78:1086–95.
Google Scholar
Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19:673–94.
Google Scholar
Rudnizky S, Khamis H, Malik O, Melamed P, Kaplan A. The base pair-scale diffusion of nucleosomes modulates binding of transcription factors. Proc Natl Acad Sci USA. 2019;116:12161–6.
Google Scholar
Rudnizky S, Bavly A, Malik O, Pnueli L, Melamed P, Kaplan A. H2A.Z controls the stability and mobility of nucleosomes to regulate expression of the LH genes. Nat Commun. 2016;7. https://pubmed.ncbi.nlm.nih.gov/27653784/.
Yosefzon Y, David C, Tsukerman A, Pnueli L, Qiao S, Boehm U, et al. An epigenetic switch repressing Tet1 in gonadotropes activates the reproductive axis. Proc Natl Acad Sci USA. 2017;114:10131–6.
Google Scholar
Wijeweera A, Haj M, Feldman A, Pnueli L, Luo Z, Melamed P. Gonadotropin gene transcription is activated by menin-mediated effects on the chromatin. Biochim Biophys Acta. 2015;1849:328–41.
Google Scholar
Haj M, Wijeweera A, Rudnizky S, Taunton J, Pnueli L, Melamed P. Mitogen- and stress-activated protein kinase 1 is required for gonadotropin-releasing hormone-mediated activation of gonadotropin α-subunit expression. J Biol Chem. 2017;292:20720–31.
Google Scholar
Melamed P. Histone deacetylases and repression of the gonadotropin genes. Trends Endocrinol Metab. 2008;19:25–31.
Google Scholar
Lim S, Luo M, Koh M, Yang M, bin Abdul Kadir MN, Tan JH, et al. Distinct mechanisms involving diverse histone deacetylases repress expression of the two gonadotropin -subunit genes in immature gonadotropes, and their actions are overcome by gonadotropin-releasing hormone. Mol Cell Biol. 2007;27:4105–20.
Google Scholar
Shalev D, Melamed P. The role of the hypothalamus and pituitary epigenomes in central activation of the reproductive axis at puberty. Mol Cell Endocrinol. 2020;518:111031.
Google Scholar
Melamed P, Haj M, Yosefzon Y, Rudnizky S, Wijeweera A, Pnueli L, et al. Multifaceted targeting of the chromatin mediates gonadotropin-releasing hormone effects on gene expression in the gonadotrope. Front Endocrinol. 2018;9:58 http://www.ncbi.nlm.nih.gov/pubmed/29535683
Glover DJ, Ng SM, Mechler A, Martin LL, Jans DA. Multifunctional protein nanocarriers for targeted nuclear gene delivery in nondividing cells. FASEB J. 2009;23:2996–3006.
Google Scholar
Ekladious I, Colson YL, Grinstaff MW. Polymer–drug conjugate therapeutics: advances, insights and prospects. Nat Rev Drug Discov. 2019;18:273–94.
Google Scholar
Mains RE, Berard CA, Denault JB, Zhou A, Johnson RC, Leduc R. PACE4: a subtilisin-like endoprotease with unique properties. Biochem J. 1997;321:587–93.
Google Scholar
Kurrikoff K, Freimann K, Veiman KL, Peets EM, Piirsoo A, Langel Ü. Effective lung-targeted RNAi in mice with peptide-based delivery of nucleic acid. Sci Rep. 2019;9:19926.
Carreras-Badosa G, Maslovskaja J, Periyasamy K, Urgard E, Padari K, Vaher H, et al. NickFect type of cell-penetrating peptides present enhanced efficiency for microRNA-146a delivery into dendritic cells and during skin inflammation. Biomaterials. 2020;262:120316.
Liu BR, Huang YW, Aronstam RS, Lee HJ. Identification of a short cell-penetrating peptide from bovine lactoferricin for intracellular delivery of DNA in human A549 cells. PLoS One. 2016;11:e0150439.
Kurrikoff K, Veiman KL, Künnapuu K, Peets EM, Lehto T, Pärnaste L, et al. Effective in vivo gene delivery with reduced toxicity, achieved by charge and fatty acid -modified cell penetrating peptide. Sci Rep. 2017;7:17056.
Kaiser UB, Conn PM, Chin WW. Studies of gonadotropin-releasing hormone (GnRH) action using nRH receptor-expressing pituitary cell lines*. Endocr Rev. 1997;18:46–70.
Google Scholar
Hazum E, Cuatrecasas P, Marian J, Conn PM. Receptor-mediated internalization of fluorescent gonadotropin-releasing hormone by pituitary gonadotropes. Proc Natl Acad Sci USA. 1980;77:6692–5.
Google Scholar
Horn F, Bilezikjian LM, Perrin MH, Bosma MM, Windle JJ, Huber KS, et al. Intracellular responses to gonadotropin-releasing hormone in a clonal cell line of the gonadotrope lineage. Mol Endocrinol. 1991;5:347–55.
Google Scholar
Zhao L, Bakke M, Krimkevich Y, Cushman LJ, Parlow AF, Camper SA, et al. Steroidogenic factor 1 (SF1) is essential for pituitary gonadotrope function. Development. 2001;128:147–54.
Google Scholar
Jorgensen JS, Quirk CC, Nilson JH. Multiple and overlapping combinatorial codes orchestrate hormonal responsiveness and dictate cell-specific expression of the genes encoding luteinizing hormone. Endocr Rev. 2004;25:521–42.
Google Scholar
Pnueli L, Luo M, Wang S, Naor Z, Melamed P. Calcineurin mediates the gonadotropin-releasing hormone effect on expression of both subunits of the follicle-stimulating hormone through distinct mechanisms. Mol Cell Biol. 2011;31:5023–36.
Sadie H, Styger G, Hapgood J. Expression of the mouse gonadotropin-releasing hormone receptor gene in αT3-1 gonadotrope cells is stimulated by cyclic 3′,5′-adenosine monophosphate and protein kinase A, and is modulated by steroidogenic factor-1 and Nur77. Endocrinology. 2003;144:1958–71.
Google Scholar
Tremblay JJ, Drouin J. Egr-1 is a downstream effector of GnRH and synergizes by direct interaction with Ptx1 and SF-1 to enhance luteinizing hormone β gene transcription. Mol Cell Biol. 1999;19:2567–76.
Google Scholar
Kaiser UB, Halvorson LM, Chen MT. Sp1, steroidogenic factor 1 (SF-1), and early growth response protein 1 (Egr-1) binding sites form a tripartite gonadotropin-releasing hormone response element in the rat luteinizing hormone-β gene promoter: an integral role for SF-1. Mol Endocrinol. 2000;14:1235–45.
Google Scholar
Melamed P, Zhu Y, Siew HTHT, Xie M, Koh M. Gonadotropin-releasing hormone activation of C-jun, but not early growth response factor-1, stimulates transcription of a luteinizing hormone β-subunit gene. Endocrinology. 2006;147:3598–605.
Google Scholar
Feng J, Lawson M, Melamed P. A proteomic comparison of immature and mature mouse gonadotrophs reveals novel differentially expressed nuclear proteins that regulate gonadotropin gene transcription and RNA splicing. Biol Reprod. 2021;79:546–61. https://pubmed.ncbi.nlm.nih.gov/18480465/
Ying Y, Yang X, Zhao K, Mao J, Kuang Y, Wang Z, et al. The Krüppel-associated box repressor domain induces reversible and irreversible regulation of endogenous mouse genes by mediating different chromatin states. Nucleic Acids Res. 2015;43:1549–61.
Google Scholar
Hammond SM, Aartsma‐Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, et al. Delivery of oligonucleotide‐based therapeutics: challenges and opportunities. EMBO Mol Med. 2021;13:e13243.
Matharu N, Ahituv N. Modulating gene regulation to treat genetic disorders. Nat Rev Drug Discov. 2020;19:757–75. Volp
Google Scholar
Dissen GA, Adachi K, Lomniczi A, Chatkupt T, Davidson BL, Nakai H, et al. Engineering a gene silencing viral construct that targets the cat hypothalamus to induce permanent sterility: an update. Reprod Domest Anim. 2017;52:354–8. Apr
Google Scholar
Guidotti G, Brambilla L, Rossi D. Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol Sci. 2017;38:406–24.
Jauset T, Beaulieu ME. Bioactive cell penetrating peptides and proteins in cancer: a bright future ahead. Curr Opin Pharmacol. 2019;47:133–40.
Xie J, Bi Y, Zhang H, Dong S, Teng L, Lee RJ, et al. Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application. Front Pharmacol. 2020;11:697.
Mullard A. Gene-editing pipeline takes off. Nat Rev Drug Discov. 2020;19:367–72. Volp
Google Scholar
Kurrikoff K, Langel Ü. Recent CPP-based applications in medicine. Expert Opin Drug Del. 2019;16:1183–91.
Saar K, Lindgren M, Hansen M, Eiríksdóttir E, Jiang Y, Rosenthal-Aizman K, et al. Cell-penetrating peptides: a comparative membrane toxicity study. Anal Biochem. 2005;345:55–65.
Google Scholar
Arukuusk P, Pärnaste L, Oskolkov N, Copolovici DM, Margus H, Padari K, et al. New generation of efficient peptide-based vectors, NickFects, for the delivery of nucleic acids. Biochim Biophys Acta Biomembr. 2013;1828:1365–73.
Google Scholar
Maenhoudt C, Santos N, Fontbonne A. Suppression of fertility in adult dogs. Reprod Domest Anim. 2014;49:58–63.
Massei G, Miller LA. Nonsurgical fertility control for managing free-roaming dog populations: a review of products and criteria for field applications. Theriogenol Theriogenol. 2013;80:829–38.
Goericke-Pesch S, Wehrend A, Georgiev P. Suppression of fertility in adult cats. Reprod Domest Anim. 2014;49:33–40. SUPPL.2
Google Scholar
Munks MW. Progress in development of immunocontraceptive vaccines for permanent non-surgical sterilization of cats and dogs. Reprod Domest Anim. 2012;47:223–7.
Google Scholar
Fischer A, Benka VAW, Briggs JR, Driancourt MA, Maki J, Mora DSO, et al. Effectiveness of GonaCon as an immunocontraceptive in colony-housed cats. J Feline Med Surg. 2018;20:786–92.
Google Scholar
DiGangi BA, Grijalva J, Jaramillo EPP, Dueñas I, Glenn C, Cruz MEC, et al. Post-operative outcomes of surgical and chemical castration with zinc gluconate in dogs presenting to veterinary field clinics. Vet J. 2017;229:26–30.
Google Scholar
Hay BA, Li J, Guo M. Vectored gene delivery for lifetime animal contraception: overview and hurdles to implementation. Theriogenology. 2018;112:63–74. May
Google Scholar
Johnson AK, Jones RL, Kraneburg CJ, Cochran AM, Samoylov AM, Wright JC, et al. Phage constructs targeting gonadotropin-releasing hormone for fertility control: evaluation in cats. J Feline Med Surg. 2020;22:685–95. Aug
Google Scholar
Dissen GA, Lomniczi A, Boudreau RL, Chen YH, Davidson BL, Ojeda SR. Targeted gene silencing to induce permanent sterility. Reprod Domest Anim. 2012;47:228–32.
Google Scholar
Olson OC, Joyce JA. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer. 2015;15:712–29.
Google Scholar
